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Abstract 
 
In 2012, the Food and Drug Administration approved a combination medication named 
TruvadaÒ (tenofovir/emtricitabine) as a prophylactic treatment to prevent HIV transmission. 
TruvadaÒ is also known as pre-exposure prophylaxis (PREP). PREP is a one-pill-a-day regimen 
proven to be 99% effective against HIV-1 transmission from sex and intravenous drug injection 
when taken daily. The uptake of PREP remains low because primary care providers fail to 
identify patients who meet the requirements to start PREP and fail to prescribe PREP for patients 
at risk. The purpose of this quality improvement project was to increase the uptake of PREP in 
patients at risk of HIV acquisition. The overall objective was to implement the U.S. Preventive 
Services Task Force screening guidelines for HIV acquisition risk and implement the guidelines 
recommended by the CDC for PREP in primary care. The providers were asked to screen all 
patients aged 19 to 65 years for risk of HIV acquisition during a well visit, prescribe PREP upon 
patients’ consent, and monitor the patients on PREP according to the standard of care. The 
outcomes were evaluated by retrospective chart review to ensure that 85% of the patients aged 
19 to 65 years for the risk of HIV acquisition were screened. Furthermore, the providers were 
asked to offer PREP to 85% of patients deemed at risk and then closely monitor those on PREP 
for side-effects, renal function, and sexually transmitted infections to remain compliant with the 
standard of care and the evidence-based guidelines. Of a total of 32 well visits, the providers 
screened 29 (91%) patients. Twenty-two patients were identified to be at substantial risk, and 
providers offered PREP to 19 (86%) patients. Three patients agreed to take PREP, and the rest 
refused. The providers prescribed PREP according to the standard of care for all three (100%) 
patients. Results showed that using the Well Visit Forms (WVFs) and the evidence-based 
guidelines for PREP in the primary care setting increased the number of patients identified as at 
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risk for HIV, increased the uptake of PREP, and assisted the providers in following the standard 
of care in prescribing PREP.  
 Keywords: PREP, primary care, TruvadaÒ, HIV 
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Incorporating HIV Pre-Exposure Prophylaxis in Primary Care 
 
HIV infection has been an epidemic in the United States since the 1980s. HIV infection 
has taken many lives since its breakout and continues to infect people worldwide. In 2012, the 
Food and Drug Administration approved a combination medication named TruvadaÒ 
(tenofovir/emtricitabine) as a prophylactic treatment to prevent HIV transmission. TruvadaÒ is 
also known as pre-exposure prophylaxis (PREP). PREP is one pill a day regimen that has proven 
to be 99% effective against HIV-1 transmission from sex and intravenous drug injection when 
taken daily (CDC, 2019). The CDC predicted that 1.2 million adults in the United States might 
benefit from PREP (Silapaswan et al., 2016). However, the uptake of PREP has been 
significantly low. The literature cited six most common barriers to adoption and implementation 
of PREP in primary care practice¾cost and financial coverage, implementation logistics, 
eligibility determination, adherence concerns, side effects, and anticipated behavior change, also 
cited as risk compensation (Calabrese et al., 2016). In 2017, new HIV diagnoses in the United 
States reached 38,739, and 52% (19,968) of those diagnoses were in the South (CDC, 2019). 
According to the San Antonio Metropolitan Health District (2017), the rate of new HIV 
diagnoses in Texas in 2016 were reported 16.1 per 100,000 people, and the rate of new HIV 
diagnoses in 2016 for Bexar County was reported 18.7 per 100,000 people. Despite the approval 
of the very effective PREP in 2012 and published guidelines for prescription and treatment in 
2014, the uptake of PREP and the number of prescriptions given to the patient remains low 
(Petroll et al., 2017). 
This project addressed some of the barriers to implementation of PREP in the primary 
care clinic. The main focus of the project was (a) to identify the patients at risk for contracting 
HIV, (b) to offer PREP to all the patients who are at risk of acquiring HIV infection, and (c) to 
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prescribe PREP for all of the appropriate candidates of PREP according to the standard of care 
through modifying providers’ practice. 
Statement of the Problem 
The problem was that not enough primary care providers (PCPs) identify the patients 
who are at risk for HIV infection or prescribe PREP for the PREP candidates. The CDC 
estimated 1.2 million individuals had an indication for PREP in 2015 (Silapaswan et al., 2016), 
but uptake of PREP had not been commensurate with the need (Garner et al., 2018). Although 
the CDC published guidelines for PREP in 2014, PCPs and HIV specialists had contradictory 
beliefs about the appropriate PREP providers. The contradictory beliefs were referred to as the 
“purview paradox,” meaning that PCPs believed that HIV specialists should handle the 
identification of appropriate candidates to receive PREP, while HIV specialists did not encounter 
enough HIV-uninfected patients who met the criteria for getting PREP prescriptions (Silapaswan 
et al., 2016). Some PCPs expressed that after a brief educational intervention on PREP criteria 
and treatment regimen, the intervention increased their willingness to prescribe PREP in the 
primary care clinics (Clement et al., 2017). Therefore, the lack of sufficient knowledge was an 
obstacle in the adoption and implementation of PREP among PCPs. 
Background and Significance 
 The Food and Drug Administration approved TruvadaÒ in 2012 for HIV pre-exposure 
prophylaxis; in July 2014, the CDC published the electronic format of guidelines for PREP and 
updated the guidelines in 2017 to revise and add developing evidence without any changes to 
graded recommendations. Despite all the efforts and advancements, the uptake of PREP 
remained low (Adams & Balderson, 2016; Calabrese et al., 2016), and the incidence of HIV 
remained practically unchanged in the United States (CDC, 2019). The southern part of the 
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country had the highest percentage (52%) of the new HIV diagnoses in 2018 (CDC, 2019), and 
Texas was included in the highest prevalence region of the country. According to the CDC 
(2019), 1 out of 7 individuals who were HIV-infected, were unaware of their infection (CDC, 
2019).  
Furthermore, statistics showed that approximately 40,000 new HIV diagnoses appeared 
each year in the United States (CDC, 2017). Therefore, it was crucial to adopt PREP in the 
primary care arena as the standard of care to identify the patients at risk and to prescribe PREP 
according to the evidence-based guidelines. Taking a thorough sexual health history aids the 
providers in identifying the risk of HIV acquisition. Unfortunately, there were no accurately 
validated tools to identify the risk for HIV acquisition available for providers. The sexual history 
was often not assessed due to anticipated discomfort of the patient, discomfort of the provider, or 
urgent issues during a visit (CDC, 2017).  
In this project, the providers were asked to perform the risk assessment during well visits 
(annual visit). The CDC and the U.S. Preventive Services Task Force (USPSTF) had developed 
the criteria for risk assessment (Appendix A) according to the epidemiologic data and enrollment 
criteria of PREP clinical trials to guide the assessment of individuals who may be at risk 
(USPSTF, 2019). The USPSTF and the CDC recommended that individuals who met one of the 
criteria in Table 1 to be considered for PREP. The adolescents were excluded from the guidelines 
due to lack of sufficient data on the possible adverse effects of PREP on this age group (CDC, 
2017). The clinical trials of PREP provided incomplete data on the possible harmful effects of 
the PREP regimen on individuals younger than age 19 years; therefore, this project was designed 
to exclude adolescents younger than 19 years of age.  
 





Sexually active men who have Inconsistent with condom use 
sex with men History of bacterial sexually transmitted disease 
   in the past 6 months 
 Have a serodiscordant sex partner 
 
Sexually active women who have  Inconsistent with condom use 
sex with men History of bacterial sexually transmitted disease 
   in the past 6 months 
 Have a serodiscordant sex partner 
 
Individuals who inject drugs Inconsistent with condom use 
sex with men History of bacterial sexually transmitted disease 
   in the past 6 months 
 Have a serodiscordant sex partner 
 Share the use of drug injecting equipment 
 
Adults who engage in transactional sex 
 
From USPSTF guidelines: Preexposure prophylaxis for the prevention of HIV infection by the 
U.S. Preventive Services Task Force, 2019. https://jamanetwork.com/journals/jama/fullarticle/ 
2735509 
From Preexposure prophylaxis for the prevention of HIV infection in the United States¾2017 
update: A clinical practice guideline, 2017 by the Centers for Disease Control and Prevention, 
2017. U.S. Public Health Service. https://www.cdc.gov/hiv/pdf/risk/PREP/cdc-hiv-PREP-
guidelines-2017.pdf 
 
Assessment of the Practice 
 Assessment of the rural family medicine clinic revealed the need for this quality 
improvement project as PREP was only prescribed if the patients initiated the evaluation request. 
Furthermore, patients who were prescribed PREP in the past were not monitored according to the 
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standard of care. The project location was a private primary care clinic in Castle Hills in San 
Antonio, Texas. There were two providers in the clinic, a Family Nurse Practitioner and a 
Medical Doctor. The clinic employed two medical assistants who oversaw taking vital signs, 
documenting the vitals, and preauthorizing and performing phlebotomy. There were three front 
desk clerks with rotating schedules during the week who oversaw checking in the patients, 
making appointments, and answering phone calls. The clinic saw patients aged 10 years and 
older.  
Organizational Readiness for Change 
 It was determined that there was an opportunity to improve potential income by 
incorporating PREP guidelines in this clinic. The providers agreed that implementing the CDC 
guidelines through this quality improvement project would significantly improve patient 
outcome and expressed readiness for implementing the project interventions.  
Project Identification 
Purpose 
 The pre-exposure prophylaxis guidelines for the prevention of HIV infection in the 
United States (CDC, 2017) necessitated the incorporation of PREP in primary care for adults 
aged 65 years and younger. The purpose of the project was to incorporate PREP guidelines 
published by the CDC and the USPSTF to facilitate identification of the individuals at risk of 
HIV acquisition and to prescribe PREP according to the standard of care.  
Objectives 
The objectives of this project were the following: 
1. Providers were to screen 85% of the patients aged 19 to 65 years during a well visit 
for the risk of HIV acquisition within the 10-week implementation period. 
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2. Providers were to offer PREP to 85% of the patients identified to be at risk for HIV 
acquisition within the 10-week implementation period.  
3. Providers were to prescribe and monitor the patients on PREP according to the 
standard of care 100% of the time in the 10-week implementation period. The 
providers were to order HIV status, Hepatitis B Virus (HBV) status, and renal 
function panel laboratory tests before PREP prescription to meet the standard of care. 
Anticipated Outcomes 
 It was anticipated that by implementing CDC and USPSTF guidelines, the number of 
patients screened for risk of HIV acquisition would increase by 85%. It was anticipated that 85% 
of the patients deemed at risk of HIV acquisition would be offered a PREP prescription. Finally, 
100% of the patients who were offered PREP and received a prescription for PREP were to be 
monitored according to the standard of care provided by the CDC and the USPSTF. The standard 
of care for PREP prescription included confirmation of HIV status, Hepatitis B status, and renal 
function status laboratory tests at the time of PREP prescription.  
Summary and Strength of Evidence 
 Approximately 40,000 new cases of preventable HIV infection were identified in the 
United States annually. The CDC estimated that 1.2 million individuals had the indications for 
using PREP in 2018, although only 18.1% of those individuals had been prescribed PREP 
(Harris et al., 2019). In February of 2019, the Trump administration announced a national 
initiative, Ending the HIV Epidemic: A Plan for America, that called for enhanced efforts to 
prevent new HIV infection with PREP as one of its major strategies (U.S. Department of Health 
and Human Services, 2019). The goal was to cover 50% of the individuals who had the 
indications for PREP. Substantial improvement was required to reduce the number of new 
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infections. The USPSTF issued a recommendation with high certainty (Grade A) for clinicians to 
offer PREP to individuals who were at substantial risk of HIV acquisition. The coverage of 
PREP increased from 9% in 2016 to 18.1% in 2018 (Harris et al., 2019). 
The CDC (2017) recommended the oral daily dose of TruvadaÒ for PREP for prevention 
of HIV infection in sexually active adult men who have sex with men, heterosexually active 
adult men and women, and adult persons who injected drugs who were at risk of HIV acquisition 
according to the USPSTF risk assessment criteria mentioned in Figure 1 (Ia) and Appendix A. 
Sexually active men and women in a relationship with HIV-infected individuals (serodiscordant 
couples) should be offered PREP to protect the HIV-uninfected partner (IIb). PREP for 
adolescents should be weighed carefully because the current data on the safety and efficacy of 
PREP for adolescents are insufficient (Ia). The negative HIV status and negative hepatitis B 
status must be confirmed before directing the patients to take TruvadaÒ and every 3 months after 
that due to the risk of drug-resistance and hepatitis B flare-up, respectively (Ia). Baseline renal 
function must be confirmed before PREP prescription and every six months thereafter to ensure 
that the renal function is normal (Ia) (CDC, 2017).  
Multiple studies that examined providers’ behavior and attitude regarding PREP revealed 
that purview paradox and risk compensation were the most common barriers to prescribing 
PREP among providers. The PCPs assumed that infection control specialists were the providers 
with the proper expertise to identify and treat persons at risk. The infection control specialists 
argued that PCPs had far more opportunities to identify HIV-uninfected individuals at risk. 
Several PCPs expressed unfamiliarity with PREP guidelines, and the standard of care was a 
barrier to adopting PREP in routine clinical practice (Silapaswan et al., 2016).  
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The CDC guidelines recommended that PCPs incorporate HIV risk assessment and PREP 
prescription in routine practice (CDC, 2017). Providers were also concerned about the efficacy 
and safety of PREP. According to several double-blinded randomized control trials, TruvadaÒ 
was 99% effective in preventing HIV when used according to the clinical guidelines. Current 
data suggested that PREP had no severe safety concerns; however, Tenofovir had been 
associated with decreased bone mineral density and renal toxicity in patients with HIV infection. 
Therefore, it was recommended that the providers monitor the patients on PREP regimen closely 
for renal toxicity and reduction in bone mineral density (CDC, 2017). The CDC did not 
recommend routine bone mineral density imaging for patients on PREP unless there were signs 
and symptoms of decreased bone mineral density, such as bone pain and unexplained fractures 
(CDC, 2017).  
Method 
 This project was implemented using the “Plan-Do-Study-Act” quality improvement 
method. The interventions and the anticipated outcomes were discussed with the providers at the 
clinic. The providers and the project leader agreed on the 10-week implementation period and 
the individuals involved in the cycle were determined to be the providers. Both providers 
enthusiastically agreed to gather data using the Well Visit Form (WVF) found in Appendix B 
and to keep the filled-out WVFs at the designated location at the clinic to comply with the Health 
Insurance Portability and Accountability Act. The project leader audited the charts on the 
electronic health record and identified the patients who met the age qualification and compared 
the findings with the documented data on the WVFs by the providers. The analyzed data were 
discussed with the providers on a weekly basis.  
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Project Intervention 
Data collected from the clinic revealed that before the implementation of project 
interventions, 0% of the patients had been prescribed PREP according to the standard of care. 
The providers, although familiar with PREP, expressed the need for a quick guide to the standard 
of care and risk assessment. Therefore, there was a one-page guide to risk assessment from the 
USPSTF and CDC guidelines posted in every exam room and on the walls by the physician 
documentation area. Every exam room had a transparent plastic pouch containing the WVF to 
remind the providers to fill out the form during the well visits (annual exams). The filled-out 
WVFs were to be kept at the clinic and used for evaluation and retrospective chart review.  
The providers were asked to assess patients aged 19 to 65 years for the risk of HIV 
acquisition during annual visits and offer PREP to the patients at substantial risk according to the 
USPSTF and CDC guidelines for PREP. The providers were to fill out the WVFs to keep track 
of the patients they had screened. The data were collected along with the WVFs every week and 
compared with the electronic health record data to determine whether the patients at risk were 
screened, offered PREP, and prescribed PREP. 
Barriers and Facilitators 
 The organizational barrier discovered during the implementation phase was the providers 
were failing to complete the WVF with every annual encounter consistently. The failure to 
consistently fill out the WVFs made it necessary to post the WVFs on the wall of every exam 
room next to the guidelines to make the forms more accessible and remind the providers to 
perform the risk assessment. 
 The coronavirus pandemic showed to be the most impactful barrier to this project as the 
number of visits to the clinic began to decline in March and April. The pandemic took attention 
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away from the benchmarks that the clinic was to make and, subsequently, negatively impacted 
this project. The providers were not as focused on this project after the shelter-in-place orders 
that started in March 2020. The facilitator felt that the project did not impose any extra work for 
the ancillary staff (e.g., Medical Assistants, Front Desk Clerk).  
Results 
The project coordinator evaluated the results from the 10-week implementation using 
Microsoft Excel for data analysis. The sample population consisted of 32 patients aged 19 to 65 
years, with a median age of 37.5 years. The project coordinator chose to implement this project 
only for annual visits because the HIV risk assessment and PREP were preventative measures, 
and they should have been addressed during annual visits. The sick visits may take attention 
away from the preventative measure. Figure 1 shows the sample population by sex.  
Figure 1 
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Results by Objective 
Objective 1 
Objective. Providers were to screen 85% of the patients aged 19 to 65 years during a well 
visit for the risk of HIV acquisition within the 10-week implementation period. 
Result. Of a total of 32 qualifying annual visits, 29 (91%) patients were screened for risk 
of HIV acquisition. Therefore, this objective was met.  
Objective 2 
Objective. Providers were to offer PREP to 85% of the patients identified as at risk for 
HIV acquisition within the 10-week implementation period.  
Result. Of 29 patients screened, 22 (69%) were identified as being at substantial risk of 
HIV acquisition. The providers offered PREP to 19 (86%) patients; therefore, this objective was 
met.  
Objective 3 
Objective. Providers were to prescribe and monitor the patients on PREP according to the 
standard of care 100% of the time in the 10-week implementation period.  
Result. Only three patients decided to start the PREP regimen. The providers prescribed 
PREP for all three patients (100%) according to the clinical guidelines. Therefore, this objective 
was met. The rest of the patients refused the offer for a PREP prescription.  
Results by Number of Patients and by Percentage 
Figure 2 shows the results by the number of patients in each category and Figure 3 shows 
the results by the percentage.  
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Figure 2    
Results by Number of Patients 
 
 
Figure 3   




 Despite the published guidelines for PREP since 2014, the uptake of this potentially 































At Risk Screened Not Screened PrEP Offered PrEP Accepted Guidelines
Followed
  PREP            PREP 
Offered   Accepted 
 
    REP                   PREP 
  Offered             Accepted 
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benefit from PREP to reduce the incidence of HIV infection in the United States. Incorporating 
PREP in the primary care arena as routine preventative care was simple, practical, and viable. 
The patients who were at risk of HIV acquisition could be easily assessed, and the PCPs were 
qualified to identify the risk and offer PREP to those who were at substantial risk. 
 The process has proven to be a viable method for identifying the patients at risk of 
acquiring HIV infection, as supported by the 2014 and the 2017 update of the HIV pre-exposure 
prophylaxis guidelines. The essential aspects of the process were the simplicity and 
sustainability. The process was easily transferable to other practices, and any primary care 
practice can adopt, adjust, and incorporate this process to fit the practice’s needs. 
Limitations 
 The novel coronavirus pandemic drove the providers’ focus toward the extreme infection 
control measures and away from the implementation of this project. Simultaneously, the number 
of annual visits declined in the clinic as people began to follow the shelter-in-place and social 
distancing orders in early March 2020. 
Recommendations 
 After the initial implementation of this process, the clinic continued to offer PREP to the 
individuals who were at substantial risk of HIV acquisition. The patients who refused PREP 
(84%) may require more education to fully understand the risk of HIV acquisition. The CDC 
website provided a HIV Risk Estimator tool that can be easily accessed by providers and 
patients. The HIV Risk Estimator tool quantified the risk of HIV acquisition based on the type of 
sexual activity; the users can see how much PREP can reduce the risk of HIV acquisition by 
itself or in combination with other modalities, such as condoms.  
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Implications for Practice 
 Implementing the CDC and USPSTF guidelines for HIV pre-exposure prophylaxis with 
the WVF increased the uptake of PREP within an urban clinic in San Antonio, Texas. Although 
many patients refused PREP, the providers raised awareness of the option to prevent HIV 
infection among the patients. Furthermore, the providers were educated about the standard of 
care for prescribing PREP. Finally, the providers were educated on how to identify the patients at 
risk for HIV acquisition accurately. 
Not only were the providers able to identify the patients at risk for HIV acquisition, but 
they were also able to offer PREP to most of the patients at risk and prescribe PREP according to 
the standard of care. The CDC and USPSTF guidelines for PREP provided information for the 
providers to easily and safely adopt and follow the standard of care for HIV pre-exposure 
prophylaxis in the primary care clinics, where it belongs. 
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• Sexually active men who have sex with men and have one of 
the following: 
§ Inconsistent use of condoms  
§ An STI within the past 6 months 
§ A serodiscordant sex partner   
• Heterosexually active women and men who have one of the 
following characteristics: 
§ Inconsistent use of condoms with a sex partner of unknown HIV 
status 
§ An STI within the past 6 months 
§ A serodiscordant sex partner 
• Individuals who inject drugs and have one of the following: 
§ Risk of sexual acquisition of HIV (based on the above criteria) 
§ Shared use of drug injection equipment 
• Individuals who engage in transactional sex 
From USPSTF guidelines: Preexposure prophylaxis for the prevention of HIV infection by the 
U.S. Preventive Services Task Force, June 11, 2019. https://jamanetwork.com/journals/jama/ 
fullarticle/2735509 
 




1. Confirm negative HIV status 
2. Confirm normal renal function 
3. Confirm negative Hepatitis B status or history of vaccination 
Prescribe Daily oral dose of TruvadaÒ (emtricitabine 200 mg/tenofovir disoproxil 300 
mg) ≤ 90 days 
Follow up Follow-up visits at least every 3 months to provide the following: 
1. HIV test 
2. STI symptom assessment 
3. Assess and educate patient’s adherence to the regimen.  
At first 3 months and every 6 months thereafter renal function and STI 
test (including 
From Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2017 
Update: A Clinical Practice Guideline by the Centers for Disease Control and Prevention, 2017. 
U.S. Public Health Service. https://www.cdc.gov/hiv/pdf/risk/PREP/cdc-hiv-PREP-guidelines-
2017.pdf 
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Appendix B 
 
Well Visit Form 
 
Patient Names:    Age/Sex:   Date:  
 
 
Is the patient at risk for acquiring HIV? Yes  No 
 
PREP Offered? Yes  No 
 
PREP accepted? Yes  No 
 
HIV status test ordered? Yes  No 
 
HBV test ordered/Hx of HBV vaccine? Yes  No 
 
Renal Function Panel ordered? Yes  No 
 
TruvadaÒ prescribed (for 90 days only)? Yes  No 
 
Notes: 
 
 
